• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gracell Biotechnologies Inc ADR (NQ: GRCL )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Feb 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Gracell Biotechnologies Inc ADR

    < Previous 1 2 3 4 5 6 Next >
    Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
    LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of... 
    Via Talk Markets
    A Preview Of Gracell Biotechnologies's Earnings
    Via Benzinga
    The Latest Analyst Ratings for Gracell Biotechnologies
    Via Benzinga
    Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    4 Analysts Have This to Say About Gracell Biotechnologies
    Via Benzinga
    Preview: Gracell Biotechnologies's Earnings
    Via Benzinga
    Bitfarms And Other Big Stocks Moving Lower On Friday
    U.S. stocks traded mixed, with the Dow Jones gaining around 90 points on Friday. Shares of Bitfarms Ltd. (NASDAQ: BITF) shares fell sharply during Friday’s session after the company announced a C$60... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 13, 2023
    Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
    Via Benzinga
    Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2023
    Via Benzinga
    Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq
    While ANL's IPO dropped more than 25% on its first day, netting just under $60M, private placement made up the difference. Plus: Deals, financings, trials and approvals. 
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
    From Gracell Biotechnologies Inc.
    Via GlobeNewswire
    Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
    BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
    Via Talk Markets
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.